258 related articles for article (PubMed ID: 36649564)
1. Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma.
Ye Z; Ai X; Yang K; Yang Z; Fei F; Liao X; Qiu Z; Gimple RC; Yuan H; Huang H; Gong Y; Xiao C; Yue J; Huang L; Saulnier O; Wang W; Zhang P; Dai L; Wang X; Wang X; Ahn YH; You C; Xu J; Wan X; Taylor MD; Zhao L; Rich JN; Zhou S
Cancer Discov; 2023 Apr; 13(4):974-1001. PubMed ID: 36649564
[TBL] [Abstract][Full Text] [Related]
2. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
[TBL] [Abstract][Full Text] [Related]
4. The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade.
Park JH; Kang I; Lee HK
Front Immunol; 2022; 13():1044544. PubMed ID: 36591276
[TBL] [Abstract][Full Text] [Related]
5. Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.
Chen Z; Herting CJ; Ross JL; Gabanic B; Puigdelloses Vallcorba M; Szulzewsky F; Wojciechowicz ML; Cimino PJ; Ezhilarasan R; Sulman EP; Ying M; Ma'ayan A; Read RD; Hambardzumyan D
Glia; 2020 Oct; 68(10):2148-2166. PubMed ID: 32639068
[TBL] [Abstract][Full Text] [Related]
6. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
8. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis.
Feng X; Szulzewsky F; Yerevanian A; Chen Z; Heinzmann D; Rasmussen RD; Alvarez-Garcia V; Kim Y; Wang B; Tamagno I; Zhou H; Li X; Kettenmann H; Ransohoff RM; Hambardzumyan D
Oncotarget; 2015 Jun; 6(17):15077-94. PubMed ID: 25987130
[TBL] [Abstract][Full Text] [Related]
9. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40.
Yang F; He Z; Duan H; Zhang D; Li J; Yang H; Dorsey JF; Zou W; Nabavizadeh SA; Bagley SJ; Abdullah K; Brem S; Zhang L; Xu X; Byrne KT; Vonderheide RH; Gong Y; Fan Y
Nat Commun; 2021 Jun; 12(1):3424. PubMed ID: 34103524
[TBL] [Abstract][Full Text] [Related]
10. Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.
Yeo AT; Shah R; Aliazis K; Pal R; Xu T; Zhang P; Rawal S; Rose CM; Varn FS; Appleman VA; Yoon J; Varma H; Gygi SP; Verhaak RGW; Boussiotis VA; Charest A
Cancer Immunol Res; 2023 May; 11(5):629-645. PubMed ID: 36881002
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
13. Myeloid Cells in Glioblastoma Microenvironment.
De Leo A; Ugolini A; Veglia F
Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
[TBL] [Abstract][Full Text] [Related]
14. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles.
Tian T; Liang R; Erel-Akbaba G; Saad L; Obeid PJ; Gao J; Chiocca EA; Weissleder R; Tannous BA
ACS Nano; 2022 Feb; 16(2):1940-1953. PubMed ID: 35099172
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
Front Immunol; 2021; 12():650105. PubMed ID: 34394072
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
Front Immunol; 2022; 13():964898. PubMed ID: 35967394
[TBL] [Abstract][Full Text] [Related]
18. Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms.
Xuan W; Lesniak MS; James CD; Heimberger AB; Chen P
Trends Immunol; 2021 Apr; 42(4):280-292. PubMed ID: 33663953
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
[TBL] [Abstract][Full Text] [Related]
20. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]